Tulane Business Model Competition Semi-Finalists Include 2 Biotech Startups
8 semi-finalists have been announced for the Tulane Business Model Competition. The contest was redesigned to better reward the a startup's ability to rapidly adapt to customers’ needs. It offers…
JEDCO Challenge Announces Finalists to Pitch on March 25
The second annual JEDCO Challenge will feature five emerging New Orleans startups, including four NOBIC clients and tenants: MobileQubes, Advano, GetHealthy, and PortaVision Medical (formerly 5 Star Medical). NOBIC tenant…
MicroBiome Therapeutics Reports Positive Trial Results for GI Modulator in Type 2 Diabetes
MicroBiome Therapeutics (formerly NuMe Health) announced positive top-line results from the company's clinical trial of their lead product, a microbiome modulator being developed for type 2 diabetes and prediabetes. The…
BioFund Receives One Year Extension
Recent interest in the New Orleans BioFund has been so high that the program has been extended through at least February 2015. Over 50 companies have approached NOBF seeking funding,…
MiniVax & Univ. of Rochester Enter into Option for Antibody Treatment
MiniVax, Inc. and the University of Rochester have entered into an exclusive option agreement to develop a monoclonal antibody for the treatment of Pneumocystis pneumonia based on research conducted at…
Diabetes-focused Microbiome Therapeutics raises $1.3M
"Microbiome Therapeutics (formerly NuMe Health) is running two clinical trials of a microbiome modulator designed to enhance insulin sensitivity in patients with prediabetes, and lessen adverse GI effects in those…
Health tech panelists say digital healthcare in New Orleans is growing
“While consumers are showing more interest in wearable health devices and entrepreneurs are proposing novel ways to cut cost in the medical system, there are still several opportunities (and obstacles)…
N.O. tech firm MiniVax wins BioChallenge competition
MiniVax was the winner of the 2013 BioChallenge, a pitch competition for emerging Louisiana bioscience startups. MiniVax is developing a treatment for a deadly fungal pneumonia that affects immunocompromised patients.…
New Orleans company working to treat opportunistic infections wins the BioChallenge
MiniVax, "a company developing a treatment for opportunistic infections has won the BioChallenge at the New Orleans BioInnovation Center, securing $20,000 in cash, donated professional services and the use of…
MiniVax wants to build on local HIV/AIDS work
November 15, 2013 - New Orleans CityBusiness CityBusiness is profiling the companies in the BioChallenge pitch competition. MiniVax is developing a treatment for a deadly fungal pneumonia that affects immunocompromised…